19:02 , Jan 11, 2019 |  BC Week In Review  |  Company News

Immunic plans to go public via Vital Therapies

Vital Therapies Inc. (NASDAQ:VTL) will acquire all outstanding shares of Immunic AG (Martinsried, Germany). The resulting company, which will retain Immunic's name and trade on NASDAQ, will develop Immunic’s pipeline, including IMU-838, a molecule inhibitor...
22:30 , Apr 14, 2017 |  BioCentury  |  Emerging Company Profile

Tolerating DHODH

Immunic AG is betting on the tolerability and efficacy of its oral, next-generation dihydroorotate dehydrogenase inhibitor to differentiate it from first-generation agents and give it an edge over other types of oral therapies in the...
07:00 , Oct 3, 2016 |  BC Week In Review  |  Financial News

Immunic completes venture financing

Immunic AG , Martinsried, Germany   Business: Autoimmune   Date completed: 2016-09-27   Type: Venture financing   Raised: EUR17.5 million ($19.7 million)   Investors: LSP; LifeCare Partners; Bayern Kapital; High-Tech Gruenderfonds; private investors  ...
07:00 , Sep 27, 2016 |  BC Extra  |  Financial News

Immunic raises EUR 17.5M in series A round

Immunic AG (Planegg-Martinsried, Germany) raised EUR 17.5 million ($19.7 million) in a series A round led by LSP and LifeCare Partners. Bayern Kapital, High-Tech Gruenderfonds and other private investors also participated. Immunic is developing small...
08:00 , Jan 25, 2016 |  BC Week In Review  |  Financial News

vasopharm completes venture financing

vasopharm GmbH , Wuerzburg, Germany   Business: Cardiovascular, Inflammation, Neurology   Date completed: 2016-01-21   Type: Venture financing   Raised: EUR20 million ($21.8 million)   Investors: Entrepreneurs Fund; Heidelberg Capital; Fort Rock Capital; Bayern Kapital;...
02:09 , Jan 22, 2016 |  BC Extra  |  Financial News

vasopharm raises EUR 20M

vasopharm GmbH raised EUR 20 million ($21.8 million) in a venture round co-led by existing investors Entrepreneurs Fund, Heidelberg Capital Private Equity and new investor Fort Rock Capital. Existing investors Bayern Kapital and funds advised...
07:00 , Jul 1, 2013 |  BC Week In Review  |  Financial News

vasopharm completes venture financing

vasopharm GmbH , Wuerzburg, Germany   Business: Cardiovascular, Neurology   Date completed: 6/24/13   Type: Venture financing   Raised: €5 million ($6.6 million)   Investors: HeidelbergCapital; Entrepreneurs Fund; Bayern Kapital; Hanseatic Asset Management; company director...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Financial News

AdvanceCOR completes venture financing

AdvanceCOR GmbH , Martinsried, Germany   Business: Cardiovascular   Date completed: 4/10/13   Type: Venture financing   Raised: €6.5 million ($8.4 million)   Investors: MIG Funds; Bayern Kapital; Bio-M; Hightech-Grunderfonds; KfW   Note: AdvanceCOR was...
08:00 , Jan 28, 2013 |  BC Week In Review  |  Financial News

Lophius Bioscience GmbH completes venture financing

Lophius Bioscience GmbH , Regensburg, Germany   Business: Diagnostic   Date completed: 1/22/13   Type: Venture financing   Raised: €4 million ($5.3 million)   Investors: VRD; WIC; S-Refit; High-Tech Gruenderfonds; Bayern Kapital; and other undisclosed...
07:00 , Jul 25, 2011 |  BC Week In Review  |  Financial News

Lophius Bioscience GmbH completes venture financing

Lophius Bioscience GmbH , Regensburg, Germany   Business: Other   Date completed: 7/18/11   Type: Venture financing   Raised: €1.4 million ($2 million)   Investors: S-Refit; High-Tech Gruenderfonds; Bayern Kapital  ...